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Background
Urticaria, a heterogeneous group of diseases, often can-
not be recognized by its morphology. Due to non-specific
and non-affordable diagnosis, management of urticaria,
especially chronic urticaria, is very challenging. This
guideline includes definition, causes, classification and
management of urticaria. Urticaria has a profound
impact on the quality of life and causes immense distress
to patients, necessitating effective treatment. One
approach to manage urticaria is identification and elimi-
nation of the underlying cause(s) and/or eliciting trigger
(s), while the second one is treatment aimed at providing
symptomatic relief. This guideline recommends use of
second-generation non-sedating H1 antihistamines as the
first-line treatment. The dose can be increased up to four
times to meet the expected results. In case patients still
do not respond, appropriate treatment options can be
selected depending on the cost.
First-generation antihistamines can interfere with rapid
eye movement (REM) sleep and impact on learning and
performance. New GA²LEN/EDF/EAACI/WAO guide-
lines do not recommend the use of these sedating antihis-
tamines for the routine management of CU as the first-
line agents. Second-generation antihistamines should be
considered as the first-line symptomatic treatment for
urticaria because of their good safety and tolerability pro-
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Figure 1 Results Diagram.
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file.Second-generation antihistamines in higher doses have
been shown to be effective in control of chronic sponta-
neous urticaria. This has been verified in studies using
even up to fourfold higher than recommended doses of
desloratadine, fexofenadine, levocetirizineand rupatadine.
Methods
Approach to chronic spontaneous urticaria.
Results
See Results Diagram in Figure 1.
Conclusions
Four-fold updosing of antihistamines is recommended in
urticaria management by Indian consensus statement.
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